This Project Grant awarded by the National Science Foundation (NSF) under the Computer and Information Science and Engineering (CFDA 47.070) program will support the development and testing of innovative technologies to aid the sustainable recovery of opioid use disorder (OUD). The $321,842 award to Arizona State University, doing business as Orspa, will focus on three key research tasks: 1) identifying effective physiological features to detect OUD craving across diverse populations, 2)...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a 5-year study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The research aims to: 1) characterize real-world OUD treatment trajectories in the year following hospital encounters among treatment-naive...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $159,711 to the University of California, Los Angeles (UCLA) to conduct research on the electrophysiological dynamics of acute opioid use in human reward, affect, and pain pathways. The goal of this 5-year research project is to uncover how acute opioid use impacts neural connectivity by directly recording human neuronal signals from...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
The National Institute on Drug Abuse (NIDA) awarded a $267,696 Project Grant under CFDA 93.279 - Drug Use and Addiction Research Programs to the University of Massachusetts Lowell (UML), a minority-serving institution, for the project "Enhancing Opportunities for Addiction Research in the Merrimack Valley." The project aims to expand UML's existing Public Health Informatics and Technology (PHIT) program by creating a new PHIT-AR (Addiction Research) track. This will recruit diverse...
This Project Grant award, with a total funding amount of $958,629, was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support the real-world adoption of an innovative digital health therapeutic called KIOS, which uses nonlinear control theory to track multiple symptoms (e.g., craving, mood, pain) and deliver personalized, evidence-based intervention strategies to patients with opioid use disorder...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop and evaluate a customized version of the "MyTrials" remote biomarker capture system for use in decentralized clinical trials (DCTs) for substance use disorders (SUDs). The key products and services to be delivered include: 1) Refinement of the existing MyTrials prototype to support the...
This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a mechanistic study to investigate how targeting the orexin system affects symptoms related to neurofunctional domains associated with opioid use disorder (OUD) and insomnia. The total award amount is $2,285,443 and the project period runs from September 30, 2024 to July 31, 2029. The study, led by Virginia Commonwealth University, will...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,415,940 to the University of Massachusetts Medical School (UMass Medical) to conduct a prospective, observational study on using digital biomarkers from wearable sensors to understand craving patterns during medications for opioid use disorder (MOUD) treatment.
The key goals are to: 1) curate a high-quality dataset of craving patterns during MOUD, 2) model craving trajectories and examine factors related to opioid use outcomes, and 3) develop clinically-informed digital phenotypes to predict MOUD treatment responsiveness. The University of Texas at Tyler received a $601,740 sub-award to develop machine learning algorithms to identify digital biomarkers of craving from the wearable sensor data. This project aims to provide critical insights into using digital tools to enhance MOUD treatment and support precision medicine approaches for opioid use disorder.